Skin-to-skin care for procedural pain in neonates.
Celeste Johnston, Marsha Campbell-Yeo, Timothy Disher...
https://pubmed.ncbi.nlm.nih.gov/28205208Actively Recruiting
Led by University of British Columbia · Updated on 2025-01-01
30
Participants Needed
1
Research Sites
26 weeks
Total Duration
U
University of British Columbia
Lead Sponsor
W
Women's Health Research Institute of British Columbia
Collaborating Sponsor
Researchers are studying preterm infants born between 26 and 30 weeks gestational age who spend time in the neonatal intensive care unit (NICU). The study evaluates whether using Calmer, a special therapy bed designed to mimic skin-to-skin care (SSC) by providing an artificial skin surface, heartbeat sounds, and breathing motion based on the parents' recordings, can support better physical growth and brain development compared to standard NICU care. This pilot randomized controlled trial aims to test the feasibility and effects of using Calmer over 2 to 3 weeks in preterm infants. In the trial, 30 preterm infants will be randomly assigned to either receive standard NICU care or use the Calmer device placed in their incubator for a minimum total of 3 hours per day over 2 to 3 continuous weeks. Calmer use can be discontinuous and is intended for times when parents are unavailable or infants cannot be held. The device settings are customized daily based on each infant's heart and breathing rates, which are recorded by nurses and parents. The study monitors infants during this treatment period to assess impact on growth and brain activity. Participants will be assessed before and after the treatment period, with measurements including daily weight gain, head circumference, body length, and brain electrical activity using EEG during rest and routine diaper changes. The study also tracks trial feasibility by monitoring consent rates, protocol adherence, data completeness, and safety over 48 months. Parents will be trained to help measure and communicate vital signs to support device programming. The total participation includes the 2 to 3 week treatment phase plus monitoring and follow-up.
CONDITIONS
Creating a Calmer NICU: Optimizing Growth and Brain Development in Preterm Infants
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 2 to 3 weeks
Participants in the Calmer group will have the Calmer device placed and left in the infant incubator for a minimum of 2 and maximum of 3 weeks. Calmer treatment is provided for a minimum total of 3 hours per day, which may be discontinuous. The research and bedside nurses record infant heart and respiratory rates daily to program the device. Parents are trained to self-measure resting heart and breathing rates for remote updates if needed.
Daily interactions with research and bedside nurses during hospital stay
Total: 1 location
1
British Columbia Women's Hospital and Health Centre
Vancouver, British Columbia, Canada, V6H 3N1
Actively Recruiting
M
Manon Ranger, PhD
L
Lindsay Richter, MSc
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Celeste Johnston, Marsha Campbell-Yeo, Timothy Disher...
https://pubmed.ncbi.nlm.nih.gov/28205208Liisa Holsti, Karon MacLean, Timothy Oberlander...
https://pubmed.ncbi.nlm.nih.gov/31041426Manon Ranger, Arianne Albert, Karon MacLean...
https://pubmed.ncbi.nlm.nih.gov/33490850Nicholas Williams, Karon MacLean, Ling Guan...
https://pubmed.ncbi.nlm.nih.gov/30770034Tanis R Fenton, Jae H Kim
https://pubmed.ncbi.nlm.nih.gov/23601190